U.S. regulators have approved the first gene therapy designed to treat a rare inherited form of hearing loss, marking a significant step forward in the treatment of certain genetic conditions affecting children.
The newly approved therapy, developed by Regeneron and named Otarmeni, is intended for children whose hearing loss is caused by mutations in the OTOF gene. This condition is extremely uncommon and is estimated to affect only a small number of babies in the United States each year.
According to the company, the treatment will be provided free of charge to eligible patients in the U.S., an unusual decision in a field where advanced gene therapies can often cost vast sums. The approval was granted through an FDA priority review pathway designed to accelerate access to potentially important new treatments.
Doctors involved in the clinical research described the therapy as a major development for affected families. Unlike cochlear implants, which are currently the main treatment option for children with this kind of genetic deafness, the new approach aims to address the condition at its source by replacing the faulty gene responsible for producing otoferlin, a protein essential for transmitting sound signals from the inner ear to the brain.
The FDA’s decision was based on a study involving 20 children with the OTOF mutation who received a one-time treatment in one or both ears. Trial results showed measurable hearing improvement in 16 of the 20 participants, while several children developed the ability to detect very soft sounds, including whispers.
Reported side effects included middle ear infection or inflammation, nausea, vomiting and dizziness. The therapy is administered through a surgical procedure under general anesthesia, in a process comparable to operations used for cochlear implants.
Although the medicine itself will be available at no cost in the United States, the broader medical expenses tied to the procedure and hospital care may still vary. The treatment has not yet been approved outside the U.S., and no international price has been announced.
The approval is being seen as an important milestone not only for hearing-loss treatment, but also for the broader future of gene-based medicine, as researchers continue exploring ways to correct rare disorders at the genetic level.
